S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

DURECT Stock Forecast, Price & News

-0.05 (-4.67%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
476,020 shs
Average Volume
1.04 million shs
Market Capitalization
$232.06 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.



DURECT Corp. focuses in advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.


Ardelyx (NASDAQ:ARDX) vs. DURECT (NASDAQ:DRRX) Head-To-Head Survey
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$30.11 million
Book Value
$0.28 per share


Net Income
$-580 thousand
Net Margins
Pretax Margin




Free Float
Market Cap
$232.06 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.85 out of 5 stars

Medical Sector

762nd out of 1,391 stocks

Pharmaceutical Preparations Industry

365th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

DURECT (NASDAQ:DRRX) Frequently Asked Questions

Is DURECT a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DURECT stock.
View analyst ratings for DURECT
or view top-rated stocks.

How has DURECT's stock price been impacted by COVID-19 (Coronavirus)?

DURECT's stock was trading at $1.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DRRX shares have decreased by 38.2% and is now trading at $1.02.
View which stocks have been most impacted by COVID-19

When is DURECT's next earnings date?

DURECT is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for DURECT

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings data on Monday, November, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.01. The specialty pharmaceutical company had revenue of $2.17 million for the quarter, compared to analyst estimates of $2.18 million. DURECT had a negative trailing twelve-month return on equity of 58.72% and a negative net margin of 280.15%. During the same quarter in the prior year, the business earned ($0.05) EPS.
View DURECT's earnings history

What price target have analysts set for DRRX?

3 brokerages have issued twelve-month price objectives for DURECT's shares. Their forecasts range from $6.00 to $8.00. On average, they expect DURECT's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 586.3% from the stock's current price.
View analysts' price targets for DURECT
or view top-rated stocks among Wall Street analysts.

Who are DURECT's key executives?

DURECT's management team includes the following people:
  • James E. Brown, President, Chief Executive Officer & Director
  • Judy R. Joice, Senior VP-Operations & Corporate Quality Assurance
  • Michael H. Arenberg, Chief Financial Officer & Secretary
  • Wei Qi Lin, Executive Vice President-Research & Development
  • David J. Ellis, Vice President-Clinical Development

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by many different institutional and retail investors. Top institutional shareholders include Lion Point Capital LP (6.81%), BlackRock Inc. (6.30%), Ingalls & Snyder LLC (3.21%), Geode Capital Management LLC (1.70%), Renaissance Technologies LLC (1.31%) and Beirne Wealth Consulting Services LLC (1.04%). Company insiders that own DURECT stock include Judy R Joice and Lp Bleichroeder.
View institutional ownership trends for DURECT

Which institutional investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Millennium Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, Ingalls & Snyder LLC, Goldman Sachs Group Inc., The Manufacturers Life Insurance Company , and Citadel Advisors LLC.
View insider buying and selling activity for DURECT
or view top insider-selling stocks.

Which institutional investors are buying DURECT stock?

DRRX stock was purchased by a variety of institutional investors in the last quarter, including Healthcare Value Capital LLC, Lion Point Capital LP, Kings Point Capital Management, Beirne Wealth Consulting Services LLC, Geode Capital Management LLC, Barclays PLC, SG Americas Securities LLC, and GSA Capital Partners LLP.
View insider buying and selling activity for DURECT
or or view top insider-buying stocks.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $1.02.

How much money does DURECT make?

DURECT has a market capitalization of $232.06 million and generates $30.11 million in revenue each year. The specialty pharmaceutical company earns $-580 thousand in net income (profit) each year or ($0.11) on an earnings per share basis.

How many employees does DURECT have?

DURECT employs 81 workers across the globe.

What is DURECT's official website?

The official website for DURECT is www.durect.com.

Where are DURECT's headquarters?

DURECT is headquartered at 10260 BUBB RD, CUPERTINO CA, 95014.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at [email protected], or via fax at 408-777-3577.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.